[go: up one dir, main page]

WO2002029098A3 - Genetic factors affecting the outcome of viral infections - Google Patents

Genetic factors affecting the outcome of viral infections Download PDF

Info

Publication number
WO2002029098A3
WO2002029098A3 PCT/GB2001/004472 GB0104472W WO0229098A3 WO 2002029098 A3 WO2002029098 A3 WO 2002029098A3 GB 0104472 W GB0104472 W GB 0104472W WO 0229098 A3 WO0229098 A3 WO 0229098A3
Authority
WO
WIPO (PCT)
Prior art keywords
outcome
viral infections
factors affecting
genetic factors
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/004472
Other languages
French (fr)
Other versions
WO2002029098A2 (en
Inventor
Adrian Hill
Lyna Zhang
Angela Frodsham
Mark Thursz
Howard Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to AU2001292125A priority Critical patent/AU2001292125A1/en
Publication of WO2002029098A2 publication Critical patent/WO2002029098A2/en
Anticipated expiration legal-status Critical
Publication of WO2002029098A3 publication Critical patent/WO2002029098A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There is disclosed a method of predicting the outcome of a viral infection in a human subject, the method comprising screening for the presence or absence in the genome of said subject of one or more polymorphic variants of the IL10RB gene or of one or more polymorphic variants in linkage disequilibrium with or in close physical proximity to a polymorphic locus in the IL10RB gene. The method is particularly useful as a genetic screen to predict the outcome of diseases caused by hepatitis B virus, hepatitis C virus and HIV.
PCT/GB2001/004472 2000-10-05 2001-10-05 Genetic factors affecting the outcome of viral infections Ceased WO2002029098A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292125A AU2001292125A1 (en) 2000-10-05 2001-10-05 Genetic factors affecting the outcome of viral infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0024442.6 2000-10-05
GB0024442A GB0024442D0 (en) 2000-10-05 2000-10-05 Genetic factors affecting the outcome of viral infections

Publications (2)

Publication Number Publication Date
WO2002029098A2 WO2002029098A2 (en) 2002-04-11
WO2002029098A3 true WO2002029098A3 (en) 2003-10-16

Family

ID=9900751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004472 Ceased WO2002029098A2 (en) 2000-10-05 2001-10-05 Genetic factors affecting the outcome of viral infections

Country Status (3)

Country Link
AU (1) AU2001292125A1 (en)
GB (1) GB0024442D0 (en)
WO (1) WO2002029098A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505304A (en) * 2001-10-16 2005-02-24 株式会社東芝 Polymorphic markers used to assess the effectiveness of interferon therapy
DE602004030830D1 (en) * 2003-11-05 2011-02-10 Immunoclin Ltd IL-22 for the prevention of infectious diseases
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
DK2514436T3 (en) * 2007-11-07 2018-03-12 Genentech Inc IL-22 FOR USE IN TREATMENT OF MICROBIAL DISEASES
WO2010149767A1 (en) 2009-06-25 2010-12-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for determining the risk of occurence of liver fibrosis in an individual
CN102260343A (en) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 Application of recombinant human G-CSF dimer for treating nerve damage disease
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
JP5947891B2 (en) 2011-07-25 2016-07-06 ジェネロン（シャンハイ）コーポレイション リミテッドＧｅｎｅｒｏｎ （Ｓｈａｎｇｈａｉ） Ｃｏｒｐｏｒａｔｉｏｎ Ｌｔｄ． Application of G-CSF dimer in the manufacture of pharmaceuticals to treat neurodegenerative diseases
CN103182072B (en) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 Application of interleukin-22 in treating and preventing nerve injuries and neurodegeneration diseases
EP2903634A1 (en) * 2012-10-03 2015-08-12 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza
EP2970422B1 (en) 2013-03-15 2018-04-18 F.Hoffmann-La Roche Ag Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
ES2930351T3 (en) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd An IL-22 dimer for use in the treatment of necrotizing enterocolitis
WO2019123398A1 (en) * 2017-12-21 2019-06-27 New Zealand Health Innovation Hub Management Limited Method of analysis of mutations in the hepatitis b virus and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013875A1 (en) * 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
WO2000008215A1 (en) * 1998-08-07 2000-02-17 Imperial College Of Science, Technology And Medicine Predicting the outcome of virus infections
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013875A1 (en) * 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
WO2000008215A1 (en) * 1998-08-07 2000-02-17 Imperial College Of Science, Technology And Medicine Predicting the outcome of virus infections
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HÖHLER T ET AL: "A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY. ENGLAND MAR 1998, vol. 111, no. 3, March 1998 (1998-03-01), pages 579 - 582, XP002235140, ISSN: 0009-9104 *
HÖHLER T ET AL: "Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection.", JOURNAL OF MEDICAL VIROLOGY. UNITED STATES MAR 1998, vol. 54, no. 3, March 1998 (1998-03-01), pages 173 - 177, XP009007671, ISSN: 0146-6615 *
KOTENKO S V ET AL: "IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A SECOND CHAIN OF THE INTERLEUKIN-10 RECEPTOR COMPLEX", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 16, no. 19, 1997, pages 5894 - 5903, XP002046438, ISSN: 0261-4189 *
KOTENKO SERGEI V ET AL: "Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2725 - 2732, XP002186669, ISSN: 0021-9258 *
LEGARE R D ET AL: "CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome.", LEUKEMIA (BASINGSTOKE), vol. 11, no. 12, December 1997 (1997-12-01), pages 2111 - 2119, XP009007556, ISSN: 0887-6924 *
SPENCER SUSAN D ET AL: "The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 4, 16 February 1998 (1998-02-16), pages 571 - 578, XP002235139, ISSN: 0022-1007 *
THURSZ M ET AL: "Influence of MHC class II genotype on outcome of infection with hepatitis C virus", LANCET, XX, XX, vol. 354, no. 9196, 18 December 1999 (1999-12-18), pages 2119 - 2124, XP004263267, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
GB0024442D0 (en) 2000-11-22
AU2001292125A1 (en) 2002-04-15
WO2002029098A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
WO2002029098A3 (en) Genetic factors affecting the outcome of viral infections
WO2007127801A3 (en) Hepatitis c virus infection biomarkers
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
Briese et al. Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis
DK1747023T3 (en) Methods and compositions for reducing HCV virus genomes in a target cell
Olinger et al. Multiple genotypes and subtypes of hepatitis B and C viruses in Belarus: similarities with Russia and western European influences
Mihm Activation of type I and type III interferons in chronic hepatitis C
AU2003216523A1 (en) Treatment of pre-core hepatitis b virus mutant infections
MXPA03000061A (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof.
ATE507293T1 (en) CONSERVED HBV AND HCV SEQUENCES SUITABLE FOR GENE SILENCING
WO2000078990A3 (en) Search method for resistance to anti-proteases of a strain of the hiv 2 virus from a biological sample taken from a patient
WO2003031934A3 (en) Identification of oligonucleotides for the capture, detection and quantitation of hepatitis b viral dna
EA200401362A1 (en) ANTI-VIRUS THERAPY, BASED ON THE RESISTANCE OF RNA
WO2003053332A3 (en) Composition and method for treating viral infection
WO2007031867A3 (en) A hepatitis c virus non-stru tural ns3/4a fusion gene
WO2006043100A3 (en) Methods for genotyping hcv
Bélec et al. Lack of association between chronic hepatitis and hepatitis G virus infection in Senegal
RU98107390A (en) METHOD FOR HEPATITIS C VIRUS IDENTIFICATION IN HUMAN BLOOD SERUM
WO2009116884A3 (en) Human papillomavirus detection kit and assay
EP1327687A4 (en) METHOD FOR INFECTING THE HEPATITIS C VIRUS
Jacq Regulations of the transcriptome adaptations to cellular environment: the yeast multidrug resistance phenomenon
WO2001071030A3 (en) Genetic determinant for chronic inflammatory disease
Ali et al. IL28B rs12979860 Genotypes is not useful for predicting treatment response over Pakistani Hepatitis-C infected patients treated for Sofosbuvir based therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP